214 related articles for article (PubMed ID: 32433002)
1. Tumor-targeted Drug Delivery by Nanocomposites.
Baker A; Khan MS; Iqbal MZ; Khan MS
Curr Drug Metab; 2020; 21(8):599-613. PubMed ID: 32433002
[TBL] [Abstract][Full Text] [Related]
2. Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment.
Chen B; Dai W; He B; Zhang H; Wang X; Wang Y; Zhang Q
Theranostics; 2017; 7(3):538-558. PubMed ID: 28255348
[TBL] [Abstract][Full Text] [Related]
3. Promising effects of nanomedicine in cancer drug delivery.
Wakaskar RR
J Drug Target; 2018 Apr; 26(4):319-324. PubMed ID: 28875739
[TBL] [Abstract][Full Text] [Related]
4. [The development of novel tumor targeting delivery strategy].
Gao HL; Jiang XG
Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
[TBL] [Abstract][Full Text] [Related]
5. Smart nanoparticles with a detachable outer shell for maximized synergistic antitumor efficacy of therapeutics with varying physicochemical properties.
Yin T; Liu J; Zhao Z; Dong L; Cai H; Yin L; Zhou J; Huo M
J Control Release; 2016 Dec; 243():54-68. PubMed ID: 27702595
[TBL] [Abstract][Full Text] [Related]
6. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy.
Hou M; Gao YE; Shi X; Bai S; Ma X; Li B; Xiao B; Xue P; Kang Y; Xu Z
Acta Biomater; 2018 Sep; 77():228-239. PubMed ID: 30006314
[TBL] [Abstract][Full Text] [Related]
8. A novel in situ hydrophobic ion paring (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system.
Song YH; Shin E; Wang H; Nolan J; Low S; Parsons D; Zale S; Ashton S; Ashford M; Ali M; Thrasher D; Boylan N; Troiano G
J Control Release; 2016 May; 229():106-119. PubMed ID: 27001894
[TBL] [Abstract][Full Text] [Related]
9. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
10. Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles.
Niu Y; Zhu J; Li Y; Shi H; Gong Y; Li R; Huo Q; Ma T; Liu Y
J Control Release; 2018 May; 277():35-47. PubMed ID: 29545106
[TBL] [Abstract][Full Text] [Related]
11. Analysis on the current status of targeted drug delivery to tumors.
Kwon IK; Lee SC; Han B; Park K
J Control Release; 2012 Dec; 164(2):108-14. PubMed ID: 22800574
[TBL] [Abstract][Full Text] [Related]
12. Bottom up design of nanoparticles for anti-cancer diapeutics: "put the drug in the cancer's food".
Needham D; Arslanagic A; Glud K; Hervella P; Karimi L; Høeilund-Carlsen PF; Kinoshita K; Mollenhauer J; Parra E; Utoft A; Walke P
J Drug Target; 2016 Nov; 24(9):836-856. PubMed ID: 27646195
[TBL] [Abstract][Full Text] [Related]
13. Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer.
Gupta P; Jani KA; Yang DH; Sadoqi M; Squillante E; Chen ZS
Expert Opin Drug Metab Toxicol; 2016; 12(3):281-9. PubMed ID: 26799671
[TBL] [Abstract][Full Text] [Related]
14. Rapid and soft formulation of folate-functionalized nanoparticles for the targeted delivery of tripentone in ovarian carcinoma.
Tomasina J; Poulain L; Abeilard E; Giffard F; Brotin E; Carduner L; Carreiras F; Gauduchon P; Rault S; Malzert-Fréon A
Int J Pharm; 2013 Dec; 458(1):197-207. PubMed ID: 24084450
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticles for tumor targeted therapies and their pharmacokinetics.
Wang J; Sui M; Fan W
Curr Drug Metab; 2010 Feb; 11(2):129-41. PubMed ID: 20359289
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic model for quantifying the effect of vascular permeability on the choice of drug carrier: a framework for personalized nanomedicine.
Kirtane AR; Siegel RA; Panyam J
J Pharm Sci; 2015 Mar; 104(3):1174-86. PubMed ID: 25583443
[TBL] [Abstract][Full Text] [Related]
17. Nanotherapeutics to overcome conventional cancer chemotherapy limitations.
Chidambaram M; Manavalan R; Kathiresan K
J Pharm Pharm Sci; 2011; 14(1):67-77. PubMed ID: 21501554
[TBL] [Abstract][Full Text] [Related]
18. 'Smart' nanoparticles as drug delivery systems for applications in tumor therapy.
Fang Z; Wan LY; Chu LY; Zhang YQ; Wu JF
Expert Opin Drug Deliv; 2015; 12(12):1943-53. PubMed ID: 26193970
[TBL] [Abstract][Full Text] [Related]
19. Nanocarriers for cancer-targeted drug delivery.
Kumari P; Ghosh B; Biswas S
J Drug Target; 2016; 24(3):179-91. PubMed ID: 26061298
[TBL] [Abstract][Full Text] [Related]
20. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.
Nakamura H; Fang J; Maeda H
Expert Opin Drug Deliv; 2015 Jan; 12(1):53-64. PubMed ID: 25425260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
